Media
-
Proactive: Racura Oncology Receives FDA Orphan Drug Designation Extension For Bisantrene RC220
The United States Food and Drug Administration (FDA) has extended Orphan Drug Designation (ODD) to our proprietary formulation of bisantrene, RC220, for acute myeloid leukemia. Racura CEO Dr Daniel Tillett spoke with Proactive about this significant announcement and the commercial advantage that the ODD will bring to bisantrene. Read the full report here.
-
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Racura Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process. Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability to deliver both anti-cancer and cardioprotection, and its current stage of clinical development. He also answers a range of questions from…
-
Demystifying Clinical Trials & Approval Processes
In Hot Copper’s recent webinar “Demystifying clinical trials and approval processes for ASX-listed companies”, CEO Dr Daniel Tillett spoke with Sonia Madigan to discuss Racura Oncology’s journey through the drug development process. Dr Tillett shared insights into the company’s unique market position and potential growth opportunities with lead drug, bisantrene. You can watch Daniel’s interview…
-
The “Racura” To Beat Cancer
Racura CEO Dr Daniel Tillett sits down with Juliette Saly at ausbiz for a check-in on the company’s performance in the last quarter, and the outlook for the rest of the year. Dr Tillett says one of the most notable achievements in the quarter was the news that Racura’s RC220 bisantrene formulation met all cGMP…
-
Racura CEO Discusses Benefits Of Resurrecting Abandoned Drugs With Stockhead
Racura CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or underutilised drugs. Dr Tillet explains how commercial decisions contribute to whether a drug makes it to market or not. He further lists examples of companies that succeeded in drug repurposing. Read the full article here
-
WTF With Racura Oncology: Changing The Chemo Game – Stockhead
Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects of traditional chemotherapy and the importance of protecting heart health as patients go through cancer treatment. The damage to the heart is one of the most serious side effects of cancer treatment, as the heart…
-
Shareholder Options Q&A
We thank all our shareholders for their strong interest in the Racura Oncology Bonus Options and Piggyback Options Offer. We have been receiving many questions in relation to these options, so to help we have prepared a document answering the most frequently asked questions. Please CLICK HERE to access the Q&A document that includes explanations on how…
-
International Cardiometabolic Expert To Join Racura Oncology’s Scientific Advisory Board
Special Report: Racura oncology is further bolstering the expertise of its scientific advisory board with the appointment of an international cardiometabolic expert who has researched the effects of chemotherapy on cardiovascular fitness of cancer patients. Clinical-stage biopharmaceutical company Racura Oncology (ASX:RAC) has appointed Associate Professor Erin Howden, of the Baker Heart and Diabetes Institute in Melbourne, to its…
-
Racura Oncology Looks To Accelerate Clinical Development Of Bisantrene
Racura Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Racura received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene, which is undergoing Phase II trials specifically for Acute Myeloid Leukemia. The clinical-stage biopharmaceutical…
